Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
BHC vs PBH vs PRGO vs CVS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Drug Manufacturers - Specialty & Generic
Medical - Healthcare Plans
Medical - Distribution
BHC vs PBH vs PRGO vs CVS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Distribution | Drug Manufacturers - Specialty & Generic | Medical - Healthcare Plans | Medical - Distribution |
| Market Cap | $2.14B | $2.58B | $1.61B | $111.40B | $92.15B |
| Revenue (TTM) | $10.55B | $1.10B | $4.18B | $407.90B | $403.43B |
| Net Income (TTM) | $-1.19B | $187M | $-1.82B | $2.93B | $4.76B |
| Gross Margin | 61.7% | 56.4% | 34.2% | 13.9% | 3.6% |
| Operating Margin | 22.9% | 29.2% | -4.1% | 1.5% | 1.5% |
| Forward P/E | 1.3x | 11.6x | 5.5x | 12.4x | 16.7x |
| Total Debt | $21.21B | $1.04B | $3.97B | $93.59B | $7.39B |
| Cash & Equiv. | $1.32B | $98M | $532M | $8.51B | $5.69B |
BHC vs PBH vs PRGO vs CVS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bausch Health Compa… (BHC) | 100 | 31.1 | -68.9% |
| Prestige Consumer H… (PBH) | 100 | 124.5 | +24.5% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| CVS Health Corporat… (CVS) | 100 | 138.1 | +38.1% |
| McKesson Corporation (MCK) | 100 | 464.2 | +364.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BHC vs PBH vs PRGO vs CVS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BHC is the #2 pick in this set and the best alternative if value is your priority.
- Lower P/E (1.3x vs 12.4x)
PBH ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.53, Low D/E 56.9%, current ratio 4.20x
- 16.9% margin vs PRGO's -43.5%
PRGO is the clearest fit if your priority is defensive.
- Beta 1.18, yield 9.8%, current ratio 2.76x
- 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
CVS is the clearest fit if your priority is momentum.
- +34.7% vs PRGO's -51.2%
MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs CVS's 3.5%
- PEG 0.43 vs PBH's 1.28
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (1.3x vs 12.4x) | |
| Quality / Margins | 16.9% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.04 vs PRGO's 1.18 | |
| Dividends | 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +34.7% vs PRGO's -51.2% | |
| Efficiency (ROA) | 5.7% ROA vs PRGO's -19.8%, ROIC 5.4% vs 3.7% |
BHC vs PBH vs PRGO vs CVS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
BHC vs PBH vs PRGO vs CVS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PBH leads in 1 of 6 categories
BHC leads 1 • MCK leads 1 • PRGO leads 0 • CVS leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
PBH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 369.5x PBH's $1.1B. PBH is the more profitable business, keeping 16.9% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BHC holds the edge at +10.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $10.6B | $1.1B | $4.2B | $407.9B | $403.4B |
| EBITDAEarnings before interest/tax | $3.6B | $353M | $58M | $10.5B | $6.8B |
| Net IncomeAfter-tax profit | -$1.2B | $187M | -$1.8B | $2.9B | $4.8B |
| Free Cash FlowCash after capex | $990M | $267M | $108M | $7.4B | $6.0B |
| Gross MarginGross profit ÷ Revenue | +61.7% | +56.4% | +34.2% | +13.9% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +22.9% | +29.2% | -4.1% | +1.5% | +1.5% |
| Net MarginNet income ÷ Revenue | -11.3% | +16.9% | -43.5% | +0.7% | +1.2% |
| FCF MarginFCF ÷ Revenue | +9.4% | +24.2% | +2.6% | +1.8% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.5% | -2.4% | -7.2% | +6.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.7% | -20.5% | -56.4% | +63.1% | +37.0% |
Valuation Metrics
BHC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.7x trailing earnings, PBH trades at a 80% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs PBH's 1.40x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.1B | $2.6B | $1.6B | $111.4B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $22.0B | $3.5B | $5.1B | $196.5B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 13.31x | 12.72x | -1.14x | 62.81x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.33x | 11.57x | 5.53x | 12.39x | 16.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.40x | — | — | 0.75x |
| EV / EBITDAEnterprise value multiple | 6.38x | 9.62x | 7.42x | 13.11x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 2.27x | 0.38x | 0.28x | 0.26x |
| Price / BookPrice ÷ Book value/share | 5.71x | 1.49x | 0.55x | 1.47x | — |
| Price / FCFMarket cap ÷ FCF | 2.13x | 10.62x | 11.12x | 14.27x | 17.63x |
Profitability & Efficiency
Evenly matched — PBH and MCK each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for PRGO. PBH carries lower financial leverage with a 0.57x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), PBH scores 8/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +5.9% | +10.2% | -50.7% | +3.9% | +3.0% |
| ROA (TTM)Return on assets | -4.5% | +5.3% | -19.8% | +1.1% | +5.7% |
| ROICReturn on invested capital | +8.2% | +9.1% | +3.7% | +5.0% | +5.4% |
| ROCEReturn on capital employed | +10.6% | +10.4% | +4.3% | +6.1% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | 56.36x | 0.57x | 1.35x | 1.24x | — |
| Net DebtTotal debt minus cash | $19.9B | $946M | $3.4B | $85.1B | $1.7B |
| Cash & Equiv.Liquid assets | $1.3B | $98M | $532M | $8.5B | $5.7B |
| Total DebtShort + long-term debt | $21.2B | $1.0B | $4.0B | $93.6B | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 1.43x | 7.40x | -7.20x | 2.11x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $2,039 for BHC. Over the past 12 months, CVS leads with a +34.7% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -20.6% | -10.8% | -13.5% | +10.6% | -8.5% |
| 1-Year ReturnPast 12 months | +21.8% | -32.9% | -51.2% | +34.7% | +4.6% |
| 3-Year ReturnCumulative with dividends | -4.4% | -8.3% | -58.1% | +36.6% | +106.4% |
| 5-Year ReturnCumulative with dividends | -79.6% | +18.4% | -60.1% | +17.0% | +286.9% |
| 10-Year ReturnCumulative with dividends | -79.6% | -3.7% | -77.7% | +3.5% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -1.5% | -2.8% | -25.2% | +11.0% | +27.3% |
Risk & Volatility
Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 0.43x | 1.21x | 0.13x | -0.02x |
| 52-Week HighHighest price in past year | $8.69 | $89.37 | $28.44 | $88.63 | $999.00 |
| 52-Week LowLowest price in past year | $4.41 | $51.24 | $9.23 | $58.35 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +65.9% | +61.1% | +41.2% | +98.5% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 52.3 | 36.4 | 60.9 | 69.3 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 478K | 3.4M | 7.4M | 757K |
Analyst Outlook
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: BHC as "Buy", PBH as "Buy", PRGO as "Hold", CVS as "Buy", MCK as "Buy". Consensus price targets imply 208.9% upside for PRGO (target: $36) vs 10.8% for CVS (target: $97). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $66.00 | $36.20 | $96.75 | $994.86 |
| # AnalystsCovering analysts | 38 | 17 | 36 | 41 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | +3.1% | +0.4% |
| Dividend StreakConsecutive years of raises | 2 | — | 10 | 0 | 17 |
| Dividend / ShareAnnual DPS | — | — | $1.15 | $2.67 | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% | 0.0% | 0.0% | +3.4% |
PBH leads in 1 of 6 categories (Income & Cash Flow). BHC leads in 1 (Valuation Metrics). 3 tied.
BHC vs PBH vs PRGO vs CVS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BHC or PBH or PRGO or CVS or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Prestige Consumer Healthcare Inc. (PBH) offers the better valuation at 12. 7x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BHC or PBH or PRGO or CVS or MCK?
On trailing P/E, Prestige Consumer Healthcare Inc.
(PBH) is the cheapest at 12. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Prestige Consumer Healthcare Inc. 's 1. 28x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — BHC or PBH or PRGO or CVS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: MCK returned +339. 0% versus BHC's -79. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BHC or PBH or PRGO or CVS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.
02β versus Perrigo Company plc's 1. 21β — meaning PRGO is approximately -7506% more volatile than MCK relative to the S&P 500. On balance sheet safety, Prestige Consumer Healthcare Inc. (PBH) carries a lower debt/equity ratio of 57% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BHC or PBH or PRGO or CVS or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BHC or PBH or PRGO or CVS or MCK?
Prestige Consumer Healthcare Inc.
(PBH) is the more profitable company, earning 18. 9% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBH leads at 29. 6% versus 1. 2% for MCK. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BHC or PBH or PRGO or CVS or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Prestige Consumer Healthcare Inc. 's 1. 28x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bausch Health Companies Inc. (BHC) trades at 1. 3x forward P/E versus 16. 7x for McKesson Corporation — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.
08Which pays a better dividend — BHC or PBH or PRGO or CVS or MCK?
In this comparison, PRGO (9.
8% yield), CVS (3. 1% yield), MCK (0. 4% yield) pay a dividend. BHC, PBH do not pay a meaningful dividend and should not be held primarily for income.
09Is BHC or PBH or PRGO or CVS or MCK better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
13), 3. 1% yield). Both have compounded well over 10 years (CVS: +6. 6%, BHC: -79. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BHC and PBH and PRGO and CVS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BHC is a small-cap deep-value stock; PBH is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock; CVS is a mid-cap income-oriented stock; MCK is a mid-cap high-growth stock. PRGO, CVS pay a dividend while BHC, PBH, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.